King Luther Capital Management Corp Cerus Corp Transaction History

King Luther Capital Management Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$3.38 - $4.22 $791,376 - $988,049	-234,135 Reduced 28.46%	588,521 $2.15 Million
Q3 2022 Nov 10, 2022	BUY	$3.43 - $5.83 $1.5 Million - $2.55 Million	437,566 Added 113.63%	822,656 $2.96 Million
Q2 2022 Aug 11, 2022	BUY	$4.41 - $5.69 $3,682 - $4,751	835 Added 0.22%	385,090 $2.04 Million
Q3 2021 Nov 10, 2021	BUY	$4.79 - $6.68 $1.14 Million - $1.59 Million	238,045 Added 162.81%	384,255 $2.34 Million
Q2 2021 Aug 13, 2021	SELL	$5.35 - $6.35 $439,796 - $522,001	-82,205 Reduced 35.99%	146,210 $864,000
Q1 2021 May 12, 2021	BUY	$5.68 - $7.87 $1.3 Million - $1.8 Million	228,415 New	228,415 $1.37 Million
Q1 2020 May 13, 2020	SELL	$2.87 - $5.49 $149,369 - $285,727	-52,045 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$3.84 - $4.86 $1.04 Million - $1.32 Million	-272,085 Reduced 83.94%	52,045 $220,000
Q3 2019 Nov 12, 2019	BUY	$4.86 - $6.05 $876,938 - $1.09 Million	180,440 Added 125.58%	324,130 $1.67 Million
Q2 2019 Aug 12, 2019	SELL	$4.51 - $6.6 $225,297 - $329,703	-49,955 Reduced 25.8%	143,690 $808,000
Q1 2019 May 10, 2019	BUY	$5.16 - $6.85 $999,208 - $1.33 Million	193,645 New	193,645 $1.21 Million

156

147M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $331M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of King Luther Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on King Luther Capital Management Corp with notifications on news.